Fast-track ruling in/out SARS-CoV-2 infection with rapid 0/1.5 h molecular test in patients with acute coronary syndromes.
Journal
Journal of cardiovascular medicine (Hagerstown, Md.)
ISSN: 1558-2035
Titre abrégé: J Cardiovasc Med (Hagerstown)
Pays: United States
ID NLM: 101259752
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
entrez:
6
11
2020
pubmed:
7
11
2020
medline:
15
12
2020
Statut:
ppublish
Résumé
Patients with acute coronary syndrome (ACS) often arrive in the catheterization (cath) lab directly from the field or an emergency department without an accurate triage for Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.Although in the pandemic period the treatment in the cath laboratory of high-risk ACS should not be delayed because the operators wear special protection systems, the subsequent risk of contagion in a non-Covid coronary care unit could be high in the case of patients positive for SARS-CoV-2. We tested the possibility of a fast-track protocol in 51 consecutive patients (mean age 65 ± 12 years) transferred from spokes centres or from the field to our HUB centre and admitted to our coronary care unit (CCU). Once the patient had arrived in the cath lab, the nasopharyngeal swab was performed. The real-time PCR to extract RNA for SARS-CoV-2 detection was performed with an automated rapid molecular Xpert Xpress test. Meanwhile, coronary angiography or percutaneous coronary intervention was performed if necessary. In this fast-track protocol, the time to perform nasopharyngeal swab was 11 ± 11 min; time spent to transport nasopharyngeal swab to the laboratory was 29 ± 20 min; time to detect viral nucleic acid was 68 ± 16 min. The overall time from the execution of nasopharyngeal swab to the result was 109 ± 26 min. The results were immediately put into the hospital computer system and made readily available. Depending on the test result, patients were then transferred to the regular CCU or Covid area. This study demonstrates that 0-1.5 h fast-track triage for coronavirus disease 2019 (COVID 19) is feasible in patients with ACS. The execution of nasopharyngeal swab in the cath lab and its analysis with a rapid molecular test allows rapid stratification of SARS-CoV-2 infection.
Identifiants
pubmed: 33156158
doi: 10.2459/JCM.0000000000001117
pii: 01244665-202012000-00006
doi:
Types de publication
Evaluation Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
975-979Références
Tam CF, Cheung KS, Lam S, et al. Impact of coronavirus disease 2019 (COVID-19) outbreak on ST-segment-elevation myocardial infarction care in Hong Kong, China. Circ Cardiovasc Qual Outcomes 2020; 13:e006631.
Pilz S, Theiler-Schwetz V, Trummer C. Letter by Pilz et al. Regarding article, ‘Impact of Coronavirus Disease 2019 (COVID-19) Outbreak on ST-Elevation Myocardial Infarction Care in Hong Kong, China. Circ Cardiovasc Qual Outcomes 2020; 13:e006734.
Cosentino N, Bartorelli AL, Marenzi G. Time to treatment still matters in ST-elevation myocardial infarction: a call to maintain treatment effectiveness during the COVID-19 pandemic. Eur Heart J Cardiovasc Pharmacother 2020; pvaa054doi: 10.1093/ehjcvp/pvaa054.
doi: 10.1093/ehjcvp/pvaa054
Mahmud E, Dauerman HL, Welt FG, et al. Management of acute myocardial infarction during the COVID-19 pandemic. J Am Coll Cardiol 2020; 76:1375–1384.
Chieffo A, Stefanini GG, Price S, et al. EAPCI Position Statement on invasive management of acute coronary syndromes during the COVID-19 pandemic. Eur Heart J 2020; 41:1839–1851.
Marty FM, Chen K, Verrill KA. How to obtain a nasopharyngeal swab specimen. N Engl J Med 2020; 382:e76.
Loeffelholz MJ, Alland D, Butler-Wu SM, et al. Multicenter evaluation of the Cepheid Xpert Xpress SARS-CoV-2. J Clin Microbiol 2020; 58:e00926-20.
Xpert® Xpress SARS-CoV-2: instructions for use. Sunnyvale, CA: Cepheid; 2020. Diagnostics catalog. Geneva: Stop TB Partnership Global Drug Facility. http://www.stoptb.org/assets/documents/gdf/drugsupply/GDFDiagnosticsCatalog.pdf. [Accessed 5 August 2020].
De Rosa S, Spaccarotella C, Basso C, et al. Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era. Eur Heart J 2020; ehaa409.
Choudry FA, Hamshere SM, Rathod KS, et al. High thrombus burden in patients with COVID-19 presenting with ST-elevation myocardial infarction. J Am Coll Cardiol 2020; 76:1168–1176.
Indolfi C, Gasparri C, Vicinanza C. Mitogen-activated protein kinases activation in T lymphocytes of patients with acute coronary syndromes. Basic Res Cardiol 2011; 106:667–679.
Lieberman JA, Pepper G, Naccache SN, Huang ML, Jerome KR, Greninger AL. Comparison of commercially available and laboratory developed assays for in vitro detection of SARS-CoV-2 in clinical laboratories. J Clin Microbiol 2020.
Smithgall MC, Scherberkova I, Whittier S, Green DA. Comparison of Cepheid Xpert Xpress and Abbott ID Now to Roche cobas for the rapid detection of SARS-CoV-2. J Clin Virol; 128:104428. doi: 10.1016/j.jcv.2020.104428.
Wolters F, van de Bovenkamp J, van den Bosch B, et al. Multi-center evaluation of cepheid xpert® xpress SARS-CoV-2 point-of-care test during the SARS-CoV-2 pandemic. J Clin Virol 2020; 128:104426doi: 10.1016/j.jcv.2020.104426.
doi: 10.1016/j.jcv.2020.104426
Rapid communication on the role of the GeneXpert® platform for rapid molecular testing for SARS-CoV-2 in the WHO European Region. Copenhagen: WHO Regional Office for Europe; 2020. Licence: CC BY-NC-SA 3.0 IGO.
ID now COVID-19 molecular in minutes. On the front line. https://www.globalpointofcare.abbott/en/product-details/id-now-COVID-19.html.
Mitchell SL, St George K. Evaluation of the COVID19 ID NOW EUA assay. J Clin Virol 2020; 128:104429doi: 10.1016/j.jcv.2020.104429.
doi: 10.1016/j.jcv.2020.104429
Basu A, Zinger T, Inglima K, et al. Performance of Abbott ID NOW COVID-19 rapid nucleic acid amplification test in nasopharyngeal swabs transported in viral media and dry nasal swabs, in a New York City academic institution. J Clin Microbiol 2020.
Indolfi C, Bartorelli A, Berti S, et al. Updated clinical indications for transcatheter aortic valve implantation in patients with severe aortic stenosis: expert opinion of the Italian Society of Cardiology and GISE. J Cardiovasc Med (Hagerstown) 2018; 19:197–210.
Pulignano G, Gulizia M, Baldasseroni S, et al. ANMCO/SIC/SICI-GISE/SICCH Executive Summary of Consensus Document on Risk Stratification in elderly patients with aortic stenosis before surgery or transcatheter aortic valve replacement ANMCO/SIC/SICI-GISE/SICCH Executive Summary of Consensus Document on Risk Stratification in elderly patients with aortic stenosis before surgery or transcatheter aortic valve replacement. G Eur Heart J Suppl 2017; 19: (Suppl D): D354–D369.
Pascual I, Carrasco-Chinchilla F, Benito-Gonzalez T, et al. Transcatheter mitral repair for functional mitral regurgitation according to left ventricular function: a real-life propensity score matched study. J Clin Med 2020; 9:1792.